A MODEL TO PREDICT THE POTENTIAL ROLE OF NEW ANTI-PNEUMOCOCCAL VACCINES IN BOGOTÁ, COLOMBIA (ID 739)
- Luis Felipe Reyes, Colombia
- David F. Severiche, Colombia
- Diego F. Severiche, Colombia
- Paula C. Ramirez Valbuena, Colombia
- Sandra L. Gomez, Colombia
- Katherine Carvajal,
- Alirio Bastidas, Colombia
- Edwin Silva,
- H. Vargas, Colombia
- Luis Felipe Reyes, Colombia
Abstract
Background
Anti-pneumococcal vaccines are the most effective strategy to prevent pneumococcal disease. However, the pneumococcal burden continues to be a remarkable problem worldwide. Thus, new conjugated vaccines are under development. Through the analysis of the prevalence of pneumococcal serotypes between 2005-2019, we aim to determine the theorical effect of these vaccines in Bogotá, Colombia.
Methods
This is a retrospective analysis of patients reported to a surveillance program due to invasive pneumococcal disease, between 2005 and 2019. We compared the potential serotype coverage of PCV10, PCV13, PCV15, PCV20 by age groups to determine the possible role of these vaccines in Bogotá, Colombia.
Results
A total of 2605 patients were included. In the group of children ˂5 years, PCV10 had serotype coverage of 9%, PCV13 of 27.8%, PCV15 of 28.2%, and PCV20 of 30%. In Adults ˃18 years, PCV10 covered was 11.8%, PCV13 of 26.6%, PCV15 of 27.7%, and PCV20 of 32.7% (Figure-1). Additionally, in adults ˃65 years, PCV10 covered was 10.2%, PCV13 of 26%, PCV15 of 27.4%, and PCV20 of 34%.
Conclusions
According to the most prevalent serotypes in our city, the usage of new vaccines may prevent some episodes of IPD in Bogotá, Colombia. However, further clinical, epidemiological and pharmacoeconomical studies should be performed